4P Pharma

About 4P Pharma

4P Pharma, established in 2014 by co-founders Revital Rattenbach and Itschak Lamensdorf, is a clinical-stage biotechnology firm headquartered in Lille, France, within the Institut Pasteur de Lille. The company focuses on developing treatments for severe diseases with significant unmet medical needs. CEO Revital Rattenbach, a seasoned biotech entrepreneur with a PhD in Biology and an MBA, previously founded PharmaSeed Europe and co-founded Adstem, a spin-off from Sorbonne University. This background in entrepreneurship and early-stage development directly informs 4P Pharma's strategy.

The company operates on a unique "drug regeneration" and startup studio model. It identifies and in-licenses very early-stage drug candidates from academic institutions and AI technology partners, then advances them through preclinical and early clinical development. A core part of this strategy involves creating Single Product Vehicles (SPVs), which are distinct spin-off companies, to manage the late-stage clinical development and commercialization of individual assets. This approach allows for focused advancement and tailored market access through strategic alliances. For instance, its SPV 4Moving Biotech is advancing a treatment for osteoarthritis, while 4Living Biotech is focused on acute respiratory distress syndrome. The business generates value by out-licensing these developed molecules after they have reached Phase I/IIa clinical trials.

4P Pharma's therapeutic pipeline covers a wide range of areas, including inflammatory diseases, respiratory conditions, and ophthalmology. A key project is 4P004, a potential first-in-class disease-modifying drug for osteoarthritis, which has entered Phase 2 clinical trials. Another candidate, 4P020, is being developed for Dry Age-related Macular Degeneration (dry AMD) in collaboration with the Institut de la Vision. The company leverages an open innovation model, partnering with leading academic labs and using AI-based simulations to accelerate clinical trial design and de-risk development. Since its inception, 4P Pharma has raised approximately $24.6M through multiple funding rounds, including a significant €15 million closing in April 2024 to support its growth and pipeline expansion.